I. FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $389.46M | ||||
Company | Location | Date | Amt. (M) | Details |
Amaxa GmbH | Cologne, | 6/13 | EUR13 | Amaxa completed its second financing round; investors included 3i Group Investments LP, NRW Fonds GmbH and Technomedia Kapitalbet- |
Amedis | UK | 6/13 | #4 | Amedis raised US$5.56M; investors included Merlin Biosciences Ltd., Avlar BioVentures Fund I, TTP Venture Fund and Andy Richards |
Biophage Inc. | Montreal | 6/20 | C$2.6 | Biophage raised US$1.7M in a placement with Quebec and offshore investors |
Biophage Inc. | Montreal | 6/27 | C$0.85 | Biophage completed a private placement representing about 1.4M units priced at C60 cents per unit; the financing was part of a letter of intent signed in April between the controlling shareholders of the company and Almont Capital Corp. |
Biovitrum AB | Stockholm, | 6/11 | $130 | Biovitrum raised $130M in a seed financing; investors included MPM Capital LP, Nordic Capital, MPM BioEquities, Karolinska Investment, ABN-AMRO Ventures, Carnegie Asset Management, H&B Capital and Next Gear |
Corcept | Menlo Park, | 6/20 | $27 | Corcept raised $27M in its Series C financing, which included investors Sutter Hill Ventures, Alta Partners and Maverick Capital |
Corus Pharma | Seattle | 6/6 | $18.5 | Corus raised $18.5M in its Series A financing round; investors included Burrill & Co., Cascade Investment, JP Morgan Partners and Orbimed Advisors |
Cyclacel Ltd. | Dundee, UK | 6/14 | #34 | Cyclacel completed a US$47.6M Series C placement led by INVESCO Private Capital |
Cytomation | Fort Collins, | 6/6 | $14 | Cytomation closed a $14M private placement with undisclosed U.S. and international investors |
Genicon | San Diego | 6/6 | $5 | Genicon completed a $5M second closing in its Series D financing |
Guava | Burlingame, | 6/21 | $17.5 | Guava raised $17.5M in its second round of venture financing, led by ProQuest Investments LP and Abingworth Management Ltd.; other investors were Paul Venture Capital, Skyline Ventures and Fog City Fund |
Ichor Corp. | Lyon, France | 6/18 | $2 | Ichor completed a $2M private financing from a consortium of investors advised by MFC Merchant Bank |
IntegraGen | Evry, France | 6/21 | EUR6.3 | IntegraGen raised US$5.4M in its first financing round; investors were CDC Innovation 2000, GenAvent, BioAm and Bay Tech |
Kourion | Dusseldorf, | 6/28 | EUR12 | MPM Capital LP's BioVentures II group of funds acquired a major ownership stake in Kourion |
Medgenics | Misgav, | 6/20 | $7 | Medgenics completed a Series A financing of $7M that included Alta Partners, Koor Corporate Venture Capital and Alta Berkeley Venture Partners |
Neurogenetics | San Diego | 6/25 | $9 | Neurogenetics raised $9M in its Series B financing; investors included Advent International Corp., Alta Partners, GIMV, Novartis Venture Fund and S.R. One |
NeuroSearch | Ballerup, | 6/21 | DKK | NeuroSearch completed a private placement to a limited number of Danish and international investors |
NitroMed | Bedford, | 6/14 | $31.4 | NitroMed raised $31.4M in a round led by Rho Ventures; other investors were Care Capital LLC, Morgan Stanley Venture Partners and Quintiles Transnational Corp., as well as HealthCare Ventures, Boston University's Community Technology Fund and Johnson & Johnson Development Corp. |
Screentec | Leiden, the | 6/13 | EUR6.5 | Screentec raised US$5.54M in its first round of financing; investors included Life Science Partners, Prelude Trust and Alafi Capital |
Sterix Ltd. | Oxford, UK | 6/20 | #8 | Sterix raised US$11.1M through a private financing |
VitaGen | La Jolla, | 6/28 | $14 | VitaGen raised $14M in the first closing of its Series C financing; investors were JP Morgan Partners, BD Ventures, Merrill Lynch Ventures, Perseus Biotech Advisors, Tullis-Dickerson & Co., Essex Woodlands Health Ventures, Pacific Horizon Ventures, Paragon Venture Partners II, Alta Partners, Radius Ventures, Triad Ventures Ltd. II, BCM Technologies, Orbitex Management, Banc One Venture Partners and CDIB U.S. Biotech |
II. MILESTONE PAYMENTS AND EQUITY INVESTMENTS | ||||
FROM EXISTING CORPORATE PARTNERS: $11.2M | ||||
Company | Partner | Amt. | Triggering Event | Details (Date) |
Acambis plc | Baxter | #3.5 | Equity | Acambis received the second tranche of an equity investment from Baxter, as agreed when the two set up a vaccines collaboration last year (6/13**) |
Atrix | Sanofi-Synthelabo | $3 | Milestone | Atrix received a $3M milestone payment for filing an NDA for Leuprogel One-Month Depot to treat advanced prostate cancer (6/26) |
BioMimetic | Novo A/S (unit | ND | Investment | BioMimetic received an investment from Novo A/S (6/26) |
Entelos Inc.* | R.W. Johnson | ND | Milestone | Entelos developed a PhysioLab disease simulation system for Type II diabetes, marking a milestone in the companies' partnership (6/22) |
Genome | American Home | ND | Milestone | Genome received a milestone payment from Wyeth-Ayerst, the pharmaceutical division of American Home Products (6/18) |
GPC Biotech | Byk Gulden | ND | Milestone | Company achieved a milestone by delivering seven targets in its antimicrobial alliance (6/27) |
ImClone | Merck KGaA | $0.5 | Milestone | ImClone received a $500,000 milestone payment for the randomization of patients in a Phase III trial of BEC2 in small-cell lung carcinoma (6/18) |
Ligand | Wyeth-Ayerst | ND | Milestone | Ligand initiated Phase III trials of TSE-424, triggering the milestone payment (6/22) |
MediGene | Aventis Pharma | DM2 |
MIlestone payment | MediGene received a US$878,149 milestone payment for initiating a Phase I/II trial for a vaccine against malignant melanoma (6/25) |
Metabometrix | Gene Logic Inc. | ND | Equity | Gene Logic made an equity investment in Metabometrix, concurrent to the initiation of a research collaboration (6/14) |
Orchid | AstraZeneca | ND | Milestone | Orchid achieved a milestone in its multiyear genotyping and pharmacogenetics collaboration, triggering a payment (6/29) |
Quark Biotech | Fujisawa | ND | Equity | Quark received an equity investment as part of its Series F financing (6/27) |
StemCells Inc. | Millennium Partners | $2 | Equity |
Millennium exercised an option to purchase 457,750 shares of StemCells for $2M (6/22) |
Vernalis | F. Hoffmann-La | ND | Milestone | Vernalis selected a lead clinical candidate from its collaboration in obesity, triggering the milestone payment (6/12) |
Notes: |
||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||
* Denotes privately held company. |
||||
** Denotes the date the item ran in BioWorld International. |
||||
ND = Not disclosed |
||||
FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange |